Andreas Makris - Concepedia

Author

Andreas Makris

Also Known As

A A Makris, A Makris, A. MAKRIS, A. Makris, A. Makris D. Van Hemelrijck, A.A. Makris, ANDREAS MAKRIS, Andreas Makris, Andreas. Makris, Athanasios Makris

300

Publications

10.4K

Citations

H-Index

139

Concepts

All Affiliations

Mount Vernon Cancer Centre Mount Vernon Hospital Royal Marsden NHS Foundation Trust Royal Marsden Hospital Institute of Cancer Research

About

Andreas Makris is an author at Mount Vernon Cancer Centre specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	40	3.2K
2	Engineering	19	22	1K
3	Health Sciences	15	19	988
4	Public Health	2	2	95
5	Natural Sciences	1	1	99

Andreas Makris

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update Manfred Kaufmann, Gabriel N. Hortobágyi, Aron Goldhirsch, Journal of Clinical Oncology Surgical OncologyBreast OncologyMedicinePrimary SystemicCancer Management	2006	718
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. T.J. Powles, Tamas Hickish, Andreas Makris, Journal of Clinical Oncology	1995	352
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Andreas Makris, T.J. Powles, S. Ashley, Annals of Oncology Surgical OncologyBreast OncologyMedicinePrimary Breast CancerBreast Cancer	1998	317
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial Sibylle Loibl, Frederik Marmé, Miguel Martín, Journal of Clinical Oncology	2021	310
Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer Mei-Lin W. Ah-See, Andreas Makris, N. Jane Taylor, Clinical Cancer Research	2008	262
Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results Anwar R. Padhani, Carmel Hayes, L. Assersohn, Radiology	2006	234
Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer Jian Chang, T.J. Powles, D. Craig Allred, Journal of Clinical Oncology	1999	225
Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial Catherine Van Poznak, R.A. Hannon, John R. Mackey, Journal of Clinical Oncology	2010	223
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others John M.S. Bartlett, Jane Bayani, Andrea Marshall, JNCI Journal of the National Cancer Institute	2016	210
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Russell Burcombe, Andreas Makris, P I Richman, British Journal of Cancer Surgical OncologyBreast OncologyMedicinePathologyGynecology	2004	176

Page 1